U.S. Markets closed

Merck & Co., Inc. (MRK)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
64.92-0.12 (-0.18%)
At close: 4:02PM EDT
People also watch
PFEJNJBMYLLYPG
  • MRK promising blockbuster PD1 Inhibitor Keytruda beginning combination trial with NWBO DC-Vax-L.
    NWBO shares already beginning to move up now as investors realize major positive announcements from 10 year brain cancer phase III trial are likely next week at ASCO.

    Company already announced in February that it had met the Primary Progression Free Survival Endpoint and that not yet for Overall Survival but expected in this current timeframe.

    Shares have been under extreme selling pressure from negative press by the usual short seller advocates.

    Expected news could cause extreme price increase.
    https://finance.yahoo.com/news/nw-bio-announces-lifting-clinical-143000739.html

    NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached
    BETHESDA, Md., Feb. 6, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a further update about the Compa
    finance.yahoo.com
  • Merck is basking in the sunshine​ but needs to get up.... Frazier can do it!
  • Tesla
  • luv fb nvda & tsla
  • #$%$... good news are in, but stock standing and volume under average.
  • Any word on FDA ruling set for today on Keytruda? Expectations is approval and should jolt the stock to get out of this trade range. Thoughts?
  • This stock is stuck here....what will it take to move it up. Obviously good news doesn't work. Seem dead in the water with no wind for the sails.
  • MRK should be near 70
  • Charles A. Henriques ( A Global Popularity Bonanza @ linkedin.com )
    NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain
    Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration

    San Francisco Bay Area: Linkedin 1839 Connections

    Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.

    Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.

    NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.

    Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.

    QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,

    Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.

    Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.

    The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.
  • Don't be OVER EXCITED as BMY is SO FAR AHEAD and it will take Merck a while until Sales result in profits and make a dent into BMY OPTIVO------BE CAREFUL as BMY is UNDERVALUED and will be Purchased
  • NY minnow what did u do with Phands?
  • AXSM (MC $85 M)(Cash $60 M) 5x BIG Phase 3 in various indications targeting large Markets with first results in Q3 2017 = 2000% POTENTIAL..UNKNOWN low float Stock !!! A BIG LIFETIME OPPORTUNITY GUYS ! GLTA

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $60 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $85 Million
    Cash: $60.6 Million(cash runway into the first quarter of 2019.)
    Price:$3.70

    Shares Out: 23 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation April
    http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1

    HUGE Pipeline targeting Billion Dollar Markets:
    http://axsome.com/wp-content/uploads/2016/11/Axsome_Dec2016_Pipeline.png

    AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)

    Major Shareholders

    Herriott Tabuteau, MD 7 351 729 38,4%
    Fidelity Management & Research Co. 2 361 625 12,3%
    JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
    Mark Coleman, MD 647 998 3,38%
    BlackRock Fund Advisors 426 837 2,23%
    Stifel Trust Co., NA 415 279 2,17%
    The Vanguard Group, Inc. 272 189 1,42%
    Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
    JPMorgan Investment Management, Inc. 156 625 0,82%
    SSgA Funds Management, Inc. 134 688 0,70%

  • Very good review of the adenosine pathway and Corvus Pharmaceutical (CRVS)!
    www.explicitpharma.com

    ExplicitPharma – In-depth reviews of pharmaceutical industry
    www.explicitpharma.com
  • Charles A. Henriques
    NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain
    Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration
    San Francisco Bay Area 500+ 500+ connections
    Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.

    Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.

    NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.

    Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.

    QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,

    Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.

    Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.

    The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany
  • study of 123 people-------GET REAL FDA-----also missing an ingrediant????/

    CHECK OUT THE FACTS
  • Group Study of 123--------Is this a JOKE??????????/

    Read Articule------
  • MRK pops 3% on FDA news: https://finance.yahoo.com/m/c09fa7ca-199f-3965-ab40-d99bbd636932/fda-approves-combining.html Sweet!.

    FDA Approves Combining Merck’s Keytruda With Chemotherapy in Lung Cancer Patients
    U.S. health regulators approved expanding the use of Merck’s cancer drug Keytruda to include adding it to chemotherapy to treat lung cancer, broadening the drug’s potential market though evidence for the ...
    finance.yahoo.com
  • Keytruda combo has been APPROVED
  • I wonder what church phands attends now.
    Minnow is by his side always.
  • Aether CEO/Founder Ryan Franks featured in 3DPrintingIndustry.com "3D Printing - The Next 5 Years" Series along with leaders from Renishaw, Jabil, Dassault Systemes, Ultimaker, Materialise, Nano Dimension, and more.

    https://3dprintingindustry.com/news/3d-printing-next-five-years-ryan-franks-aether-ceo-founder-111604/

    MRK to start using Aether Bioprinter for pharma research?

    3D Printing The Next Five Years by Ryan Franks, Aether CEO & Founder
    This is a guest post in our series looking at the future of 3D Printing. To celebrate 5 years of reporting on the 3D printing industry, we’ve invited industry leaders and 3D printing experts to give us their perspective and predictions for the next 5
    3dprintingindustry.com